All In Biotech

Drug Trial Radar · NCT01887938

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 23, 2013

Primary completion

Feb 13, 2026

Study completion Feb 13, 2026

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Jun 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term safety data in participants with metachromatic leukodystrophy (MLD) who are receiving HGT-1110 and have participated in Study HGT-MLD-070 (NCT01510028) through Week 40.

Conditions

  • Metachromatic Leukodystrophy (MLD)

Interventions

  • HGT-1110Biological

    Participants will receive IT injection of HGT-1110.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline to Follow-up (Week 628)
  2. Presence of Anti-HGT-1110 Antibodies in Cerebrospinal Fluid (CSF) and SerumTime frame: Baseline until end of the study (Week 624)

Locations

15 sites in 7 countries. Site status is shown where the registry gives one.

  • The Children's Hospital at Westmead

    Westmead, Australia

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Detska Interni Klinika, Lf Mu A Fn Brno

    Brno, Czechia

  • Rigshospitalet

    Copenhagen, Denmark

  • Hopital Femme Mere Enfant

    Bron, France

  • Hopital Gui de Chauliac - CHRU de Montpellier

    Montpellier, France

  • CHU de Nantes

    Nantes, France

  • CHR Orleans - Hopital La Source

    Orléans, France

  • Hôpital de Bicêtre

    Le Kremlin-Bicêtre, Île-de-France Region, France

  • Klinikum Oldenburg

    Oldenburg, Germany

  • Marien-Hospital Wesel gGmbh

    Wesel, Germany

  • Center for Pediatric Clinical Studies (CPCS)

    Tübingen, Baden-Wurttemberg, Germany

  • Kitakyushu Municipal Yahata Hospital

    Fukuoka, Japan

  • Kurashiki Central Hospital

    Okayama Prefecture, Japan

  • Osaka University Hospital

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.